Bionomics, Inc.

BNC210 showed improved PTSD symptoms by Week 12, with efficacy observed from Week 4. Bionomics plans to initiate a Phase 3 study in H2 2025.

BNC210, an α7 nicotinic acetylcholine receptor-negative allosteric modulator, showed early improvement in PTSD symptoms within 4 weeks of a 12-week phase IIb study, with a significant reduction in symptom severity at week 12. Despite higher discontinuation rates due to adverse events, the trial met primary and secondary endpoints, suggesting BNC210's potential as a new treatment for PTSD.

Bionomics, a clinical-stage biotech company, highlights recent achievements including advancing BNC210 into Phase 3 for social anxiety disorder, securing funding, and planning to redomicile to the U.S. while maintaining an Australian presence. The company believes BNC210, with FDA Fast Track designations for SAD and PTSD, is undervalued and aims to leverage regulatory privileges for accelerated review and approval.